FPT-SOFTWARE
1.2.2023 09:01:43 CET | Business Wire | Press release
FPT Software Europe, a subsidiary of FPT Software - leading technology and IT service provider headquartered in Vietnam, has recently announced its strategic partnership with Covestro AG (Covestro). As a leading global manufacturer of polymer materials, Covestro is included in DAX stock market index among major German companies trading on the Frankfurt Stock Exchange.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005414/en/
FPT Tower – FPT Corporation’s head quarter in Hanoi, Vietnam (Photo: Business Wire)
Entering a multi-year agreement with Covestro, FPT Software Europe is leveraging its in-depth experience, comprehensive services and best-shore model to support the DAX-listed group in the migration of 290 applications to the Amazon Web Services (AWS) cloud platform, thereby accelerating its digital transformation journey.
Starting signal for the next generation of IT infrastructure
Within the next few years, FPT Software Europe will accompany Covestro's entire transformation process. Starting with the assessment of customer requirements, the cloud experts analyze the chemical giant's legacy systems; design and implement solutions adapted to the AWS infrastructure. FPT Software Europe's core tasks in the migration process include refactoring legacy applications to preserve their functionality in the new ecosystem while leveraging the full potential of the new platform for the customer. By moving to AWS, Covestro AG is setting itself the goal of creating greater security for productive systems and business-critical workloads. Furthermore, by cloud migration, the company achieves additional benefits such as on-demand scalability of resources, increased productivity, and reduced capital and operating costs. With the move to the cloud, Covestro is laying the foundation for further digital transformation initiatives.
DAX company benefits from cloud migration expertise
FPT Software leverages its best-shore model, which is a mix of off shore, nearshore and onsite delivery to enable fast and cost-efficient processes to serve its customers like Covestro. As an AWS Advanced Partner with 600 highly qualified, certified AWS experts and around 20,000 highly trained IT specialists, FPT Software is able to implement the project in the shortest possible time and with the highest quality.
"As part of our promise to help Covestro accelerate its cloud migration, we have rapidly assembled project teams of cloud experts who work closely with the group's contacts on a day-to-day basis," said Le Hai, CEO of FPT Software Europe. "With the combined expertise of 600 certified AWS and 300 certified Microsoft experts, as well as thousands of other developers, FPT Software Europe is always ready to help European enterprises drive large-scale cloud projects and lay a solid foundation for broader digital transformation initiatives."
Through its partnership with FPT Software Europe, Covestro benefits from the comprehensive expertise of the Vietnamese IT service provider, which has already successfully implemented extensive cloud migration and digital transformation projects for major corporations like Schaeffler, RWE, Innogy and E.On.
FPT Software Europe and Covestro are discussing about further future joint projects in other areas such as managed services, cloud services with advanced application development and SAP implementation services.
About FPT Software Europe
FPT Software Europe, headquartered in Essen, Germany, is part of global technology and IT services provider FPT Software with 25,500 employees and revenue of more than $632.5 million. A pioneer in digital transformation, the company offers world-class services in Smart factory, Digital platforms, RPA (robotic process automation), Artificial Intelligence (AI), IoT (Internet of Thing), Data analytics, Mobility, Cloud, Managed services and Testing. FPT Software serves more than 1,000+ customers worldwide, 85 of which are Fortune Global 500 companies in the industries of Aerospace & Aviation, Manufacturing & Automotive, Banking Finance Insurance, Logistics & Transportation, Healthcare & Life Sciences, Retail, Utilities & Energy, and more. For more information, visit: www.fpt-europe.de.
About Covestro
Covestro is one of the world's leading manufacturers of high-quality plastics and their components. With its innovative products and processes, the company contributes to greater sustainability and quality of life in many areas. Covestro supplies global customers in key industries such as mobility, construction and housing, and electrical and electronics. In addition, Covestro's polymers are used in areas such as sports and leisure, cosmetics, healthcare and in the chemical industry itself.
The company is fully aligned with the circular economy and aims to become climate neutral by 2035 (Scope 1 and 2). In fiscal 2021, Covestro generated sales of €15.9 billion. As of the end of 2021, the company manufactures are presenting in 50 locations worldwide and employs around 17,900 people (full-time positions).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005414/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom